Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Actavis, TPG Capital deal

    Actavis Group, Zug, Switzerland TPG Capital, Fort Worth, Texas Business: Supply/Service Actavis completed the divestiture of its Aptalis Pharmaceutical Technologies subsidiary to private investment firm TPG for an …

    Published on 5/18/2015
  • AM-Pharma, Pfizer deal

    AM-Pharma B.V., Bunnik, the Netherlands Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Renal Pfizer purchased a 17.5% equity stake in AM-Pharma and received an option acquire the remainder of the company. The option …

    Published on 5/18/2015
  • AOP Orphan, Cardiome deal

    AOP Orphan Pharmaceuticals AG, Vienna, Austria Cardiome Pharma Corp. (TSX:COM;NASDAQ:CRME), Vancouver, B.C. Business: Cardiovascular AOP Orphan granted Cardiome rights to market IV and powder formulations of Esmocard …

    Published on 5/18/2015
  • Arena, Roivant Sciences deal

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Roivant Sciences Ltd., New York, N.Y. Business: Neurology Arena granted Roivant exclusive, worldwide rights to develop and commercialize nelotanserin. Arena …

    Published on 5/18/2015
  • BioNTech, Eli Lilly deal

    BioNTech AG, Mainz, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The partners will identify and validate tumor targets and their corresponding T cell receptors (TCR) in one or more …

    Published on 5/18/2015
  • Biosearch Technologies, LGC deal

    Biosearch Technologies Inc., Novato, Calif. LGC Ltd., Teddington, U.K. Business: Supply/Service Analytical testing company LGC acquired custom oligonucleotide manufacturer Biosearch for an undisclosed cash sum. …

    Published on 5/18/2015
  • ChemRar, Lancet deal

    ChemRar High Tech Center, Khimki, Russia Lancet JSC, Moscow, Russia Business: Pharmaceuticals ChemRar and Lancet partnered to develop and commercialize drug candidates in the Eurasian Economic Union, which includes …

    Published on 5/18/2015
  • Coherus BioSciences, Baxter deal

    Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif. Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Business: Autoimmune, Biosimilars Coherus will perform preclinical development and will be eligible for …

    Published on 5/18/2015
  • Eli Lilly, Transition Therapeutics deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Transition Therapeutics Inc. (TSX:TTH;NASDAQ:TTHI), Toronto, Ontario Business: Endocrine/Metabolic Eli Lilly granted Transitions Transition Therapeutics Ireland Ltd. …

    Published on 5/18/2015
  • Evolva Holding, Emergent BioSolutions deal

    Evolva Holding S.A. (SIX:EVE), Reinach, Switzerland Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Business: Infectious Emergent acquired Evolvas EV-035 antibiotic portfolio, including preclinical melioidosis …

    Published on 5/18/2015
  • FibroGen, AstraZeneca deal

    FibroGen Inc. (NASDAQ:FGEN), San Francisco, Calif. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Hematology FibroGen received a $15 million milestone payment from AstraZeneca under a 2013 deal to develop …

    Published on 5/18/2015
  • Fondazione Tettamanti, Formula Pharmaceuticals deal

    Fondazione Matilde Tettamanti Menotti De Marchi Onlus, Monza, Italy Formula Pharmaceuticals Inc., Berwyn, Pa. Business: Cancer Fondazione Tettamanti granted Formula exclusive, worldwide rights to develop and …

    Published on 5/18/2015
  • GeoVax Labs, NIH deal

    GeoVax Labs Inc. (OTCBB:GOVX), Atlanta, Ga. National Institutes of Health, Bethesda, Md. Business: Infectious GeoVax and NIHs National Institute of Allergy and Infectious Diseases (NIAID) partnered to develop GeoVaxs …

    Published on 5/18/2015
  • GlaxoSmithKline, The ALS Association, Harvard, Massachusetts General Hospital deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. The ALS Association, Washington, D.C. Harvard University, Cambridge, Mass. Massachusetts General Hospital, Boston, Mass. Business: Neurology The ALS Association, the …

    Published on 5/18/2015
  • GlaxoSmithKline, University of North Carolina deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. University of North Carolina, Chapel Hill, N.C. Business: Infectious GlaxoSmithKline partnered with the university to establish a research center, HIV Cure, at the …

    Published on 5/18/2015
  • Immunocore, AstraZeneca deal

    Immunocore Ltd., Abingdon, U.K. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer Immunocore will conduct a Phase Ib/II trial combining its IMCgp100 with MEDI4736 and/or tremelimumab from AstraZenecas …

    Published on 5/18/2015
  • Indiana University, University of Alabama at Birmingham, La Jolla Pharmaceutical deal

    Indiana University, Indianapolis, Ind. University of Alabama at Birmingham, Birmingham, Ala. La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Business: Musculoskeletal, Pulmonary IUs research and technology …

    Published on 5/18/2015
  • Lexicon, Bristol-Myers deal

    Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), The Woodlands, Texas Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Neurology Lexicon and Bristol-Myers selected an undisclosed neuropathic pain candidate for …

    Published on 5/18/2015
  • Midatech Pharma, Dana-Farber Cancer Institute deal

    Midatech Pharma plc (LSE:MTPH), Abingdon, U.K. Dana-Farber Cancer Institute, Boston, Mass. Business: Cancer, Drug delivery Midatech and Dana-Farber partnered to develop Midatechs nanomedicines to treat glioblastoma. The…

    Published on 5/18/2015
  • Opexa, Merck KGaA deal

    Opexa Therapeutics Inc. (NASDAQ:OPXA), The Woodlands, Texas Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Autoimmune In March, the partners amended a February 2013 deal granting Mercks Merck Serono division an …

    Published on 5/18/2015
  • Orexigen, Takeda deal

    Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Endocrine/Metabolic Takeda sent a letter to Orexigen seeking to terminate a deal granting …

    Published on 5/18/2015
  • PeptiDream, Merck deal

    PeptiDream Inc. (Tokyo:4587), Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Pharmaceuticals PeptiDream partnered with Merck to generate macrocyclic and constrained peptide therapeutics …

    Published on 5/18/2015
  • San Raffaele, MolMed deal

    San Raffaele Hospital, Milan, Italy MolMed S.p.A. (Milan:MLM), Milan, Italy Business: Cancer MolMed exercised an option to purchase a chimeric antigen receptor (CAR)-splice variant v6 of CD44 (CD44v6) from San Raffaele.…

    Published on 5/18/2015
  • Santen, Clearside Biomedical deal

    Santen Pharmaceutical Co. Ltd. (Tokyo:4536), Osaka, Japan Clearside Biomedical Inc., Alpharetta, Ga. Business: Ophthalmic The companies expanded their 2013 deal to identify and develop compounds from Santens pipeline to…

    Published on 5/18/2015
  • Sigma-Tau, Baxter deal

    Sigma-Tau Group, Pomezia, Italy Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Business: Cancer Baxter will purchase a portfolio of leukemia products from Sigma-Taus Sigma-Tau Finanziaria S.p.A. unit for $900 …

    Published on 5/18/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993